

Pharmacy Formulary Updates for September 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status September 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO- MA
Evenity	MB/RX;PA:SP
Skyrizi	\$3.65;PA;QL;SP
Aemcolo	\$3.65;QL
Nucala	\$3.65;PA;SP
Ruzurgi	\$3.65;PA
Ezallor	\$3.65;PA;QL
Jynarque	\$3.65
Diacomit	\$3.65;PA; additional PA/PBHMI members under 18

Key

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy